In a phase 3 trial, the agent reduces seizure frequency by up to 53% in treatment-resistant focal epilepsy, with rapid onset ...

About one-third of patients with focal epilepsy, a common form of the neurological disorder, are believed to respond poorly to available therapies. Yet they too may eventually see improvement, if not ...

Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human Phase 1/2a clinical trials for lead candidate EPY201 targeting focal refractory ...

Please provide your email address to receive an email when new articles are posted on . Monthly seizure frequency percentage reduction was 68.73% for the entire study cohort. For those followed up in ...

Please provide your email address to receive an email when new articles are posted on . Cannabidiol treatment was associated with median reduction of 67% to 99% in focal aware seizures. All ...

University of California San Diego is conducting new, Phase 2/3 national epilepsy clinical research trials, called Rise, to study BHV-7000, a novel investigational therapy, in focal epilepsy.

Longitudinal data suggested that treatment-resistant focal epilepsy may improve over time. Nearly 70% had reduced seizure frequency and some patients achieved seizure freedom. Improvement was not ...

Xenon (XENE) is in the process of nearly completing its phase 3 X-TOLE2 trial using its Kv7 potassium channel opener azetukalner for the treatment of patients with focal onset seizures [FOS]. As a ...

It takes about a year for people with focal epilepsy to start finding some relief from anti-seizure medications, a new study says. In all, 3 of 5 epilepsy patients (60%) do achieve freedom from ...

Seizures have many causes, and are either generalized or focal. Within these categories, there are several types that may affect children. It may be impossible to diagnose the reason for a child’s ...